Tempus AI Inc. surged as stocks have been trading up by 10.94 percent following highly positive AI healthcare breakthrough coverage.
Click Here for a Millionaire's POV on Trading TEM
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Positive clinical trial data with Medtronic showed Tempus AI’s platform boosted severe heart valve surgeries by 40% and specialist visits by 27% across 35 hospitals, with TEM trading up about 4.3%.
- An expanded multiyear partnership now gives Gilead Sciences enterprise-wide access to Tempus AI’s Lens platform and de-identified oncology datasets.
- ARK Invest, led by Cathie Wood, has rotated out of mega-cap tech and semis into TEM, making Tempus AI one of ARK’s largest positions despite a >20% year-to-date slide.
- A William Blair pre‑Q1 diagnostics call signals rising institutional focus on the testing and AI‑driven diagnostics space, with TEM likely on many watchlists.
Live Update At 12:32:33 EDT: On Wednesday, April 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 10.94%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Tempus AI, trading under ticker TEM, has moved from a choppy base into a sharp upswing. On 2026/03/23, TEM closed near $49.14. After some back-and-forth trading, the stock pulled down into the low $40s by 2026/04/10, with a close around $42.94. That set up a classic “shakeout then breakout” pattern many short-term traders love to stalk.
From there, momentum flipped. TEM ripped from the low $40s to a 2026/04/15 close just under $55, with an intraday high of $55.44. That’s roughly a 27% rebound in a few sessions. The intraday 5‑minute tape on the latest day shows steady higher lows from the $50 area premarket, then grinding strength through mid‑day. No violent rug-pulls, just persistent dip buying.
More Breaking News
- FIG Stock Slides As Traders Reassess High-Growth Story
- KEEL Stock Jumps As Bitfarms Rebrands Into U.S. AI Infrastructure Play
- EOSE Stock Pops As Revenue Growth And Capacity Plans Impress Traders
- Texas Pacific Land Corporation Faces Significant Stock Drop Amid Board Member’s Death
Fundamentally, Tempus AI is still a high‑growth, loss‑making name. Revenue runs around $1.27B, but margins are deeply negative, with profit margin near -19% and return on equity close to -294%. Cash is a bright spot: over $604.8M on the balance sheet and a current ratio about 3.1 give TEM room to keep funding growth. For traders, that mix — strong top line, weak earnings, ample cash — usually translates into big moves when sentiment swings.
Why Traders Are Watching Tempus AI Now
TEM is catching serious attention because the story is finally lining up with the chart. The Medtronic clinical trial news is not just another AI press release. Tempus AI showed that its automated notification platform actually changed real medical behavior: 40% more surgical interventions and a 27% jump in specialist evaluations for severe heart valve disease across 35 hospitals. That is hard, real‑world lift, and the market responded with a 4.3% pop in TEM on the headline.
For momentum traders, that kind of catalyst matters. It tells you Tempus AI is moving beyond “AI hype” into measurable clinical utility. When a platform drives more procedures, that usually means more billing, more data, and more leverage in future deals. TEM’s recent surge off the lows lines up neatly with that narrative.
Then you have the expanded multiyear partnership with Gilead Sciences. Giving Gilead enterprise‑wide access to the Tempus AI Lens platform and de‑identified multimodal oncology data screams long‑duration revenue potential. These are the sort of sticky, data‑heavy relationships that can underpin a premium multiple, especially if oncology projects grow over time.
Layer in ARK Invest rotating out of mega‑cap tech and semis into TEM — making Tempus AI one of ARK’s largest positions — and you see why volatility has picked up. ARK is leaning into the idea that AI‑driven precision medicine is the next big AI value layer. For short‑term traders, that means sharp legs up when news hits, but also fast pullbacks when the broader AI trade wobbles.
Finally, William Blair’s pre‑Q1 diagnostics call signals that institutional eyes are zooming in on this whole space. When the sell‑side starts grouping you into a core diagnostics and testing basket, the next earnings print often becomes a major trading event. For TEM, that’s the next big catalyst to watch on the calendar.
Conclusion
Tempus AI is acting like a textbook high‑beta growth stock: strong story, heavy losses, and powerful news‑driven moves. TEM’s bounce from the low $40s to the mid‑$50s has been fueled by three pillars — hard clinical data with Medtronic, an expanded Gilead partnership, and visible backing from ARK Invest. Each piece reinforces the idea that Tempus AI sits at the intersection of AI, diagnostics, and big‑pharma R&D budgets.
At the same time, the financials remind traders what they’re dealing with. TEM posts roughly $1.27B in revenue but still burns cash, with free cash flow around -$43.1M last quarter and negative returns on assets and equity. That’s why the stock can be down more than 20% year to date and still rip 25%+ in a week when sentiment flips. The balance sheet — more than $604.8M in cash and manageable debt — buys Tempus AI time, but not a free pass.
For active traders, the playbook is clear: respect the volatility, and respect your risk. Tempus AI has the kind of catalysts — clinical proof points, pharma partnerships, and institutional sponsorship — that can fuel multi‑day runs, but also brutal reversals. That’s exactly where trading discipline matters most. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” As Tim Sykes likes to hammer home, “The best traders aren’t the ones who nail every big winner — they’re the ones who cut losses fast and stay in the game long enough to catch the best setups.” TEM is shaping up as one of those high‑potential setups, for traders disciplined enough to manage it.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.